Severity and management of hypercortisolism in patients with adrenocortical carcinoma and overt Cushing's syndrome.

Rákkutatás · Adrenocortical carcinoma

The severity of cortisol excess in patients with adrenocortical carcinoma is associated with poorer survival outcomes and higher risk of tumor recurrence or progression.

The study examined how the severity of hypercortisolism influences survival in patients with Cushing’s syndrome (CS) caused by adrenocortical carcinoma (ACC). In a retrospective international cohort of 101 ACC patients, median progression‑free, disease‑free, and overall survival were 5.6, 12.3, and 19.4 months, respectively. Higher urinary free cortisol (UFC) levels and larger tumor size independently predicted metastatic disease. The probability of recurrence/progression rose with increasing cortisol excess, suggesting that hypercortisolism intensity may serve as a marker of aggressive disease.

Identifying hypercortisolism as a prognostic marker can help clinicians stratify risk, tailor surveillance, and potentially guide therapeutic intensity for ACC patients.

Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.

Eredeti forrás

Kapcsolódó jelek